Unit Director

Professor Andrew Tutt is the Director of the Breakthrough Research Unit at King’s College London, a Reader in Breast Oncology and Consultant Clinical Oncologist. He qualified in medicine from Bristol University in 1990. After postgraduate training in general medicine he trained in clinical oncology at the Royal Marsden Hospital before gaining a Research Training Fellowship from the Medical Research Council to work in Professor Ashworth’s laboratory at The Institute of Cancer Research. Here he worked on functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002. He cares for women with breast cancer as an oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust and is an faculty member of Section of Research Oncology at King’s College London.

Professor Tutt has, in collaboration with Professor Ashworth, developed a translational clinical trial programme focusing on cancers associated with functional deficiencies in BRCA1 and BRCA2. Dr Tutt’s leadership of the ICEBERG proof of concept trials for PARP inhibitors in BRCA1/2 cancers have led to a reappraisal of BRCA1/BRCA2 testing as a therapy companion diagnostic. He is currently Chief Investigator for the UKCRN Triple Negative Trial and the proposed Breast International Group Neoadjuvant PARP inhibitor Trial (NEPTUNE).